Clinical trials: Human Papillomavirus Positive Cervical Carcinoma
Cervical Cancer, Vulvar Cancer
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04425291
- Testing
- 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, HPV
Automated Cervical Cancer Screening Using a Smartphone-based Artificial Intelligence Classifier
Cervical cancer remains a major public health challenge in low- and middle-income countries (LMICs) due to financial and logistical issues.
- Trial name
- NCT04859530
- Testing
- AVC test
- Where
- Cameroon
- Volunteers
- 5,886 people, healthy volunteers welcome
- Sponsor
- Prof. Patrick Petignat
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
Digital Telecytology for Triage of HPV-Positive Women in Cameroon
This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon.
- Conditions
- Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Cancer Screening Methods
- Trial name
- NCT07550010
- Testing
- HPV testing (self-sampling), Digital telecytology, AI-assisted telecytology
- Where
- 2 sites in Cameroon
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Human Papillomavirus Infection
Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.
- Trial name
- NCT00973362
- Testing
- APTIMA HPV Assay, FDA-Approved HPV DNA Test
- Where
- 17 sites in United States
- Volunteers
- 12,896 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Cervical Cancer
CINtec PLUS Triage in HPV Primary Screening
Prospective study which will recruit participants when they attend for a routine cervical screening. The study will evaluate the use of CINtec PLUS for triage of human papillomavirus (HPV) positive participants in HPV primary…
- Trial name
- NCT03721484
- Testing
- CINtec PLUS
- Where
- United Kingdom
- Volunteers
- 9,800 people, healthy volunteers welcome
- Sponsor
- Western Health and Social Care Trust
Cervical Precancerous Lesions, Cervical Cancer
TS Triage of HR-HPV Positive Population and Its Accuracy Study
A prospective study assessing TS accuracy in HR-HPV+ women, influencing factors, and 1-year follow-up of false-positives versus biopsy.
- Trial name
- NCT07777094
- Testing
- Colposcopy and cervical biopsy, Follow-up of TS false-positive patients
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Nantong University
Human Papillomavirus Infection, Cervical Cancer
Primary Cervical Cancer Screening by Self-sampling HPV Test
Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider…
- Conditions
- Human Papillomavirus Infection, Cervical Cancer, Negative For Intraepithelial Lesion Or Malignancy, Atypical Squamous Cells of Undetermined Significance
- Trial name
- PREVENT (NCT05613283)
- Where
- 6 sites in China
- Volunteers
- 17,875 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Cervical Intraepithelial Neoplasia, Cervical Cancer
HPV Integration Testing for Human Papillomavirus-Positive Women
Papanicolaou (Pap) triage, with high specificity, has been recommended for primary Human papillomavirus (HPV) testing but is flawed by poor sensitivity and cytologist dependence.
- Trial name
- NCT02576262
- Testing
- TCT，HPV，colposcopic inspection
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Huazhong University of Science and Technology
HPV Infection, HPV-Related Cervical Carcinoma
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
A total of 480 Chinese women aged 18-26 years old were enrolle，experimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group.
- Trial name
- NCT04436133
- Testing
- Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha), 9-valent HPV vaccine（Gardasil 9）
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Oropharyngeal Cancer
Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
Cancer of the oropharynx (middle, side and back walls of the throat; back of the tongue; soft palate, and tonsils), or oropharyngeal squamous cell carcinoma (OPSCC), has been on the rise in the United States.
- Trial name
- NCT02147418
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- New Mexico Cancer Research Alliance
Cervical Cancer, Vulvar Cancer
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04422366
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Human Papillomavirus Infection, Cervical Cancer
Clinical Evaluation of Detection of High Risk HPV in Urine
Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer.
- Conditions
- Human Papillomavirus Infection, Cervical Cancer, Human Papilloma Virus, Negative for Intraepithelial Lesion or Malignancy
- Trial name
- Urine-hrHPV (NCT05210348)
- Where
- 3 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Cervical Cancer, Genital Wart
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.
- Conditions
- Cervical Cancer, Genital Wart, CIN, VIN
- Trial name
- NCT05580341
- Testing
- Zerun HPV-9, GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Oropharyngeal Cancer, HPV-Related Carcinoma
A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
The researchers think that a blood test (NavDx®) may be able to identify cancer early by looking for circulating DNA from Human Papillomavirus/HPV. Circulating DNA are small pieces of genes that are released into the bloodstream.
- Conditions
- Oropharyngeal Cancer, HPV-Related Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05814549
- Testing
- NavDx
- Where
- 7 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer, Human Papillomavirus
Accuracy of Portable Colposcopy and HPV Genotypes Among HIV+ Women
This study will evaluate the effectiveness of portable colposcopy when compared to conventional colposcopy (25x magnification of the cervix, the gold standard) and Visualization Inspection with Acetic acid (VIA, with 1x…
- Conditions
- Cervical Cancer, Human Papillomavirus, Human Immunodeficiency Virus
- Trial name
- NCT02338141
- Testing
- Portable colposcopy (Cerviscope), Conventional colposcopy (Wallach Zoomscope)
- Where
- Haiti
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Duke University
Cervix Cancer, Screen HPV-positive
Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North Carolina
The purpose of this study is to test the feasibility and acceptability of a multi-level, community-engaged intervention to increase access to cervical cancer screening using human papillomavirus (HPV) self-collection (HPVSC)…
- Trial name
- NCT07294066
- Testing
- Human papilloma virus screening
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A*0201-positive…
- Conditions
- Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, New Diagnosis Tumor, Locally Advanced
- Trial name
- NCT07172256
- Testing
- CUE-101, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yale University